Stryker Co. (NYSE:SYK) Shares Sold by QV Investors Inc.


Share on StockTwits

QV Investors Inc. lowered its stake in Stryker Co. (NYSE:SYK) by 21.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 25,600 shares of the medical technology company’s stock after selling 6,850 shares during the quarter. QV Investors Inc.’s holdings in Stryker were worth $6,236,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Curi Capital acquired a new stake in Stryker in the fourth quarter worth about $29,000. RWM Asset Management LLC acquired a new stake in Stryker in the fourth quarter worth about $33,000. Albion Financial Group UT acquired a new stake in Stryker in the fourth quarter worth about $34,000. Ossiam lifted its holdings in Stryker by 294.9% in the fourth quarter. Ossiam now owns 154 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 115 shares during the period. Finally, Graves Light Private Wealth Management Inc. bought a new stake in Stryker in the fourth quarter worth about $41,000. 71.46% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE SYK traded down $1.01 during trading hours on Monday, hitting $256.12. The stock had a trading volume of 6,401 shares, compared to its average volume of 1,218,358. The company has a market capitalization of $96.38 billion, a P/E ratio of 55.78, a P/E/G ratio of 2.79 and a beta of 0.87. The firm’s 50-day moving average price is $241.95 and its two-hundred day moving average price is $234.17. Stryker Co. has a 52 week low of $171.75 and a 52 week high of $260.00. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.15 and a current ratio of 2.89.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 26th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.55 by $0.26. The firm had revenue of $4.26 billion during the quarter, compared to analysts’ expectations of $4.33 billion. Stryker had a return on equity of 20.94% and a net margin of 12.35%. The company’s revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.49 earnings per share. As a group, analysts expect that Stryker Co. will post 7.18 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, April 30th. Shareholders of record on Wednesday, March 31st will be given a dividend of $0.63 per share. The ex-dividend date is Tuesday, March 30th. This represents a $2.52 dividend on an annualized basis and a yield of 0.98%. Stryker’s payout ratio is currently 30.51%.

Several brokerages have commented on SYK. Needham & Company LLC reiterated a “hold” rating on shares of Stryker in a research report on Thursday, January 28th. JPMorgan Chase & Co. boosted their price target on shares of Stryker from $245.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 2nd. Credit Suisse Group dropped their price target on shares of Stryker from $278.00 to $273.00 and set an “outperform” rating on the stock in a research report on Thursday, January 28th. Deutsche Bank Aktiengesellschaft boosted their price objective on Stryker from $228.00 to $251.00 and gave the stock a “buy” rating in a report on Thursday, January 28th. Finally, Truist boosted their price objective on Stryker from $210.00 to $245.00 in a report on Wednesday, January 6th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $236.27.

In other news, CFO Glenn S. Boehnlein sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, March 1st. The stock was sold at an average price of $246.01, for a total transaction of $492,020.00. Following the completion of the transaction, the chief financial officer now directly owns 12,321 shares in the company, valued at $3,031,089.21. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP M Kathryn Fink sold 4,000 shares of the company’s stock in a transaction on Thursday, April 8th. The shares were sold at an average price of $250.00, for a total value of $1,000,000.00. The disclosure for this sale can be found here. 6.80% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties.

Featured Article: What is a bull market?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.